EverQuote, Inc. - Class A (EVER)
Live price chart, market sentiment, and community perspectives for EverQuote, Inc. - Class A (NASDAQ: EVER).
Live price chart, market sentiment, and community perspectives for EverQuote, Inc. - Class A (NASDAQ: EVER).
On our desk, the valuation looks compelling relative to their fundamental performance. EverQuote just posted Q2 CY2026 revenue of $195.1 million—beating estimates by 2.6%—and delivered a GAAP EPS of $0.53 alongside a $30.1 million Adjusted EBITDA. Even with a trailing P/E sitting around 7.7 to 7.9, the stock dipped roughly 6% right after the print to the low $23 range, which looks like a classic market overreaction to a solid beat. With B. Riley raising their price target to $34, the risk-reward profile here heading into late 2026 favors accumulation for patient capital.
Looking closely at the underlying financial health in the latest reports, EverQuote is remarkably well-capitalized with $192.3 million in cash and zero debt, representing over 21% of their market capitalization. Their operating margin expanded to 12% from 9% year-over-year, and return on equity sits at a stellar 53.61%. However, looking at the risk factors outlined in their filings, we cannot ignore their structural dependence on third-party media traffic sources and a concentrated set of major property and casualty insurance providers. Any tightening in digital marketing channels or adverse shifts in PandC insurance markets could quickly compress those expanding margins.
When evaluating their technology infrastructure from a quantitative lens, EverQuote operates effectively as an AI-powered growth solutions partner and marketplace connecting consumers with top carriers for car, home, and life insurance. Their competitive moat relies heavily on proprietary consumer data assets gathered since inception and a specialized AI traffic engine. When stress-testing their business model against prospective analysts or modeling future cash flows, analysts must account for their heavy reliance on variable marketing dollars—which grew 19.3% YoY to $55.9 million in recent quarters—to sustain top-line customer acquisition momentum.
Explore plasma cleansing, somatic organ swaps, and BCI.